Zepbound 10 mg/.5mL

Tirzepatide, the active ingredient in Zepbound 10 mg/0.5 mL, is a dual GIP and GLP-1 receptor agonist presented as a 10 mg/0.5 mL injection solution for subcutaneous use. It is used in adults for chronic weight management in obesity or overweight with weight-related comorbidities, and may also be used in type 2 diabetes care according to approved labeling in some markets.[fda.gov][pubchem.ncbi.nlm.nih.gov]

GNH USA supplies Zepbound 10 mg/0.5 mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zepbound (tirzepatide) acts on incretin-related pathways involved in glucose regulation, appetite, and body weight control.[fda.gov][medlineplus.gov]

- Chronic weight management in obesity: Supports long-term weight management in adults with obesity (BMI ≥30 kg/m²) when used as part of a reduced-calorie diet and increased physical activity.[fda.gov] - Chronic weight management in overweight with comorbidities: Aids weight reduction in adults with overweight (BMI ≥27 kg/m²) plus at least one weight-related condition such as hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, or type 2 diabetes.[fda.gov] - Type 2 diabetes mellitus (market-dependent): In some regions, tirzepatide is also indicated to improve glycemic control in adults with type 2 diabetes, typically as an adjunct to diet and exercise, according to local product labeling.[fda.gov][ema.europa.eu]

Like other incretin-based therapies, tirzepatide can cause gastrointestinal and systemic adverse effects, and some serious reactions require urgent medical assessment.[fda.gov][medlineplus.gov]

Common Side Effects: - Nausea: Stomach upset or queasiness, particularly when starting treatment or increasing the dose.[fda.gov] - Vomiting: Episodes of throwing up that may accompany nausea or reduced appetite.[fda.gov] - Diarrhea: Loose or more frequent stools, sometimes with abdominal cramping.[fda.gov] - Decreased appetite: Reduced desire to eat, which may contribute to weight loss.[fda.gov]

Serious or Rare Side Effects: - Pancreatitis: Severe, persistent abdominal pain (often radiating to the back), with or without vomiting, requiring immediate evaluation.[fda.gov][medlineplus.gov] - Gallbladder problems: Symptoms such as right upper abdominal pain, fever, jaundice, or clay-colored stools, which may indicate gallstones or cholecystitis.[fda.gov] - Possible thyroid C-cell tumors: In rodent studies, tirzepatide caused thyroid C-cell tumors; patients should report neck lumps, hoarseness, dysphagia, or dyspnea.[fda.gov] - Severe allergic reactions: Swelling of face, lips, tongue, or throat, difficulty breathing, or widespread rash or hives needing urgent care.[fda.gov]

Clinical use of Zepbound (tirzepatide) requires assessment of endocrine, pancreatic, gastrointestinal, and metabolic risk factors, as well as ongoing monitoring for serious adverse reactions as outlined in the approved prescribing information.[fda.gov]

- Screen for thyroid cancer risk: Evaluate history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), as tirzepatide is contraindicated in these conditions.[fda.gov] - Monitor for pancreatitis: Advise patients to report severe, persistent abdominal pain; discontinue if pancreatitis is suspected.[fda.gov] - Assess gallbladder disease risk: Monitor for signs of cholelithiasis or cholecystitis, particularly in patients with rapid weight loss.[fda.gov] - Use in renal or hepatic impairment: Review renal and hepatic function and monitor closely in patients with pre-existing impairment, especially if gastrointestinal losses occur.[fda.gov] - Pregnancy and breastfeeding: Safety data are limited; discuss potential risks and benefits, and follow current label and guideline recommendations.[fda.gov][medlineplus.gov] - Concomitant diabetes therapies: In patients with type 2 diabetes, consider risk of hypoglycemia when tirzepatide is used with insulin or sulfonylureas and adjust as prescribed.[fda.gov] - Store at 2-8°C: Keep refrigerated in the original carton, protect from light, do not freeze, and do not shake the pre-filled device.[fda.gov]

Tirzepatide can interact with other antidiabetic medicines and may influence the absorption of orally administered drugs by delaying gastric emptying, so prescribers consider concomitant therapy carefully.[fda.gov]

Major Interactions (Avoid): - Personal or family history of MTC/MEN 2 with similar agents: Avoid combining with other GLP-1 receptor agonists where overlapping risks for thyroid C-cell tumors are a concern, following label contraindications.[fda.gov] - Severe hypersensitivity history: Avoid re-exposure in patients with previous serious allergic reaction to tirzepatide or any excipients.[fda.gov]

Moderate Interactions (Monitor Closely): - Insulin and sulfonylureas: Risk of hypoglycemia may increase; dose adjustments of these agents may be required as directed by the prescriber.[fda.gov] - Other antidiabetic drugs: Combined glucose-lowering effects warrant closer monitoring of blood glucose and individualized regimen adjustments.[fda.gov] - Narrow-therapeutic-index oral drugs: Because tirzepatide delays gastric emptying, monitor clinical response of oral medications where small changes in exposure are critical.[fda.gov] - Oral contraceptives: Delayed gastric emptying may reduce peak concentrations; labels recommend considering non-oral or backup contraception around initiation or dose escalation.[fda.gov] - Agents affecting gastric motility: Concomitant use with drugs that markedly alter GI transit may unpredictably change absorption of some oral therapies; monitor as clinically indicated.[fda.gov]